Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly

Chanson, Philippe; Boerlin, Viktor; Ajzenberg, C.; Bachelot, Y.; Benito, Pedro J.; Bringer, J.; Caron, Philippe; Charbonnel, B.; Cortet, Christine; Delemer, Brigitte; Escobar-Jiménez, Fernándo; Foubert, L.; Gaztambide, Sonia; Jockenhoevel, F; Kuhn, Jean Marc; Leclère, J; Lorcy, Y.; Perlemuter, Léon; Prestele, H; Roger, Patrick; Rohmer, V.; Santen, Richard J.; Sassolas, G; Scherbaum, Werner A.; Schopohl, Jochen; Torres, E.; Varela, C; Villamil, Facundo; Webb, Susan M.

doi:10.1046/j.1365-2265.2000.01134.x

Cited by 99 publications

(39 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OCT-LAR successfully suppresses IGF-I levels (16 -22, 32) and some authors have found that it is more effective than lanreotide (17)(18)(19)(20). The results of the present study not only confirm that 12 months' treatment with OCT-LAR reduces the thickness of both weight-bearing and non-weight-bearing joints in de novo patients with active acromegaly (as has previously been observed with lanreotide) but also show that the patients in whom disease was controlled experienced a greater reduction in joint thickening at all of the investigated sites.…”

Section: Discussionmentioning

confidence: 99%

Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly

Colao¹,

Cannavò

Marzullo³

et al. 2003

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: To evaluate the role of age, gender, duration and control of acromegaly on the reversibility of arthropathy. Patients and design: 30 de novo patients with active acromegaly, 30 cured patients and 30 healthy subjects were studied in a tranverse and an open longitudinal study design. Methods: Shoulder, wrist and knee thickening was measured by ultrasonography at study entry in all 90 subjects and after 12 months of treatment with octreotide-LAR (OCT-LAR) at a dose of 10-40 mg every 28 days in the 30 de novo patients.Results: Thickness at all joint sites was greater in the active than in the cured patients and controls ðP , 0:001Þ; and was greater in the cured patients than in the controls ðP , 0:001Þ: There was no gender difference, but joint thickness was less in the patients with disease duration . 10 years. Age significantly correlated with wrist ðr ¼ 20:55; P , 0:001Þ; right knee ðr ¼ 20:45; P ¼ 0:01Þ; and left knee thickness ðr ¼ 20:42; P ¼ 0:02Þ in patients with active disease, and with wrist thickness ðr ¼ 0:88; P , 0:0001Þ in controls. Twelve months of OCT-LAR treatment led to disease control in 18 patients (60%). There was a decrease in the thickness of the shoulder ð15:1^3:2%Þ; wrist ð20:53 :1%Þ; right knee ð22:2^3:4%Þ and left knee ð18:2^2:8%Þ in all patients but the reduction in joint thickness at all sites was greater in the patients with controlled disease after OCT-LAR treatment than in the uncontrolled patients ðP , 0:01Þ: Shoulder and right knee thickening normalized in respectively 11 (61.1%) and 16 (88.9%) well-controlled patients. Conclusions: Growth hormone and insulin-like growth factor-I (IGF-I) suppression by 12 months' OCT-LAR treatment is accompanied by a significant decrease in the thickness of both weight-bearing and non-weight-bearing joints (mainly in patients whose disease is controlled) regardless of disease duration. These findings suggest that tissue hypertrophy in the context of the acromegalic arthropathy can be improved by suppressing IGF-I levels.

show abstract

Section: Discussionmentioning

confidence: 99%

Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly

Colao¹,

Cannavò

Marzullo³

et al. 2003

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…In addition, most patients enrolled in lanreotide treatment trials were previously tested for octreotide responsiveness unlike those enrolled for octreotide LAR studies, who were sometimes treatment-naïve. If considering only GH levels <1 μg/L to be the cutoff for "normalizing" mortality, 33% of octreotide LAR Cozzi et al, 2003;Lancranjan and Atkinson, 1999;Lancranjan et al, 1996) and 25% of lanreotide SR Chanson et al, 2000a) treated patients achieved disease control, implying that ~50% of SRIF agonist treated GH-"controlled" patients may still be at higher risk for higher mortality rates. Prolonged treatment duration improves biochemical control as GH and IGF-1 plasma levels continue to decrease with time Colao et al, 2001;Cozzi et al, 2003Cozzi et al, ,2006Davies et al, 1998;Freda et al, 2005;Jallad et al, 2005;Ronchi et al, 2006).…”

Section: Biochemical Controlmentioning

confidence: 99%

Somatostatin agonists for treatment of acromegaly

Ben-Shlomo

Melmed

2008

Molecular and Cellular Endocrinology

View full text Add to dashboard Cite

The discovery of somatotropin-release inhibitory factor (SRIF) in hypothalamic extract in 1970 led to the synthesis of the first somatostatin analog octreotide, discovery of five somatostatin receptor subtypes, and development of additional somatostatin receptor ligands (SRL) as pharmacotherapy for acromegaly and other neuroendocrine tumors. Long-acting formulations of SRL (octreotide LAR Depot, lanreotide SR and lanreotide autogel) assure improved patient compliance with weekly up to monthly injections, and are commonly used as primary or adjuvant treatment of acromegaly. We review SRL currently available, emphasizing long-acting compounds and their efficacy in controlling acromegaly. Disease control is evaluated by biochemical markers, tumor shrinkage, and diseasesymptom improvement balanced against drug-related side effects.

show abstract

“…In two studies, the sample size of the patients was small (n 10 and 12), but their results were in favor of octreotide LAR (13,14). In a larger multicenter study involving 125 patients switched from lanreotide PR, we have recently shown that the GH concentrations were significantly lower after three injections of 20 mg octreotide LAR as compared with those found at the last evaluation on lanreotide PR (11). The percentages of patients with GH profile mean levels #2.5 mg/l and #1 mg/l slightly increased after the change of the treatment.…”

Section: Octreotide Lar Vs Lanreotide Prmentioning

confidence: 94%

Somatostatin analogs in the treatment of acromegaly: the choice is now possible

Chanson

2000

Eur J Endocrinol

View full text Add to dashboard Cite

Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly

Abstract: Octreotide LAR 20 mg administered once monthly was more effective than lanreotide SR 30 mg administered 2 or 3 times monthly in reducing GH and IGF-I in patients with acromegaly.

Cited by 99 publications

References 25 publications

Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly

Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly

Somatostatin agonists for treatment of acromegaly

Somatostatin analogs in the treatment of acromegaly: the choice is now possible

Contact Info

Product

Resources

About